STEVENSON, Md., May 02, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of Henry Schein, Inc. (Nasdaq:HSIC) (“Henry Schein” or the “Company”) securities during the period between February 13, 2013 and February 12, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 7, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Henry Schein securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Henry Schein was engaging in anti-competitive behavior through agreements with Benco Dental Supply Company and Patterson Companies, Inc., in violation of United States antitrust laws, and these violations of U.S. antitrust laws would result in heightened scrutiny by the federal government and a lawsuit filed by the Federal Trade Commission (“FTC”).
According to the complaint, following a February 12, 2018 FTC announcement that it filed a complaint against Henry Schein, among others, alleging violations of U.S. antitrust laws, the value of Henry Schein shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Henry Schein securities purchased on or after February 13, 2013 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9%
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock
Japan Earthquake Disrupts Auto and Chip Supply Chains
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 



